Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Bevasiranib sodium, an siRNA compound, targets and silences the genes responsible for producing vascular endothelial growth factor (VEGF). The suppression of VEGF, a critical factor in the development of choroidal neo-vascularization (CNV), aims to thwart the progression to wet age-related macular degeneration (wet AMD).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Bevasiranib sodium, an siRNA compound, targets and silences the genes responsible for producing vascular endothelial growth factor (VEGF). The suppression of VEGF, a critical factor in the development of choroidal neo-vascularization (CNV), aims to thwart the progression to wet age-related macular degeneration (wet AMD). |
Molecular Weight | N/A |
CAS No. | 849758-52-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Bevasiranib sodium 849758-52-7 inhibitor inhibit